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Institute of Liver Studies, King’s College Hospital, Denmark Hill, London, UKSummary recovery of neurological function [2–20]. The efﬁcacy of liverThe case for using emergency liver transplantation in acute liver
failure was made two decades ago by a series of single centre
experiences. The development of models identifying a poor prog-
nosis assisted the selection of patients for liver transplantation
but none of these delivers both high sensitivity and speciﬁcity
for prediction of death. Enhanced sensitivity favours the individ-
ual patient while enhanced speciﬁcity targets the pool of organs
available at those who will derive greatest beneﬁt. The non-
transplant survival rates have improved considerably for certain
cohorts of patients and these prognostic models have not been
adjusted to reﬂect these changes. The presumption of transplant
beneﬁt can no longer be taken as established in paracetamol-
related acute liver failure and a policy review is appropriate. In
other scenarios, such as seronegative hepatitis and the phenotype
of sub-acute liver failure, spontaneous survival rates remain low
and the basis for liver transplantation remains sound. Outcomes
after liver transplantation are improving but are not yet compa-
rable to elective transplantation. The understanding of factors
associated with failure after liver transplantation is improving
but accurate deﬁnition of futility has not yet been attained.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Historical background
Acute liver failure (ALF) is the most dramatic clinical situation in
which liver transplantation is performed with previously-well
patients facing likely death within days or weeks being salvaged
by surgical intervention. A National Institutes of Health consen-
sus conference on the indications for liver transplantation in
1983 considered ALF from a largely theoretical perspective [1].
By the mid-1990s, the feasibility of liver transplantation had been
established by a series of single centre experiences pointing to a
signiﬁcant success rate but with outcomes that were not as good
as for elective transplantation and with concerns about failure ofJournal of Hepatology 20
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controlled trial despite a call in 1990 for a ‘controlled trial
between specialist units. . . to establish the role of emergency
hepatic transplantation in patients with fulminant hepatic fail-
ure’ [21]. Instead, liver transplantation became an accepted treat-
ment for patients with ALF and was credited by some as being the
only effective treatment for this condition. ALF now accounts for
around 8% of liver transplant activity in Europe and the US
[22,23].
A number of prognostic models for ALF were described while
the early experience with liver transplantation was evolving and
these appeared to identify a population of patients with a high
likelihood of mortality at a point in the disease that was still com-
patible with survival after transplantation [24,25]. The under-
standing of prognosis in ALF evolved to recognise the
contribution of four key determinants:
 aetiology
 rate of progression of the disease
 age of the patient
 laboratory markers of disease severity.
The prognosis was also recognised as being somewhat coun-
ter-intuitive. The highest rate of spontaneous survival was seen
in patients with the most-dramatic clinical syndrome (hyper-
acute liver failure), greatest derangement of coagulation and
highest incidence of cerebral oedema. The worst survival was
seen in patients with slowly evolving disease (sub-acute liver
failure) with modest derangement of coagulation parameters
and relatively little risk of cerebral oedema [26].
The practice of liver transplantation for ALF over the next two
decades was largely a process of reﬁnement rather than major
advances. Numerous studies addressed prognosis in ALF and from
these a number of prognostic models emerged that were used to
select patients for emergency liver transplantation (Table 1)
[24,25,27–45]. The application of these prognostic criteria created
a tension between sensitivity and selectivity given that none of
the models performed extremely well in both respects. Reduced
sensitivity could lead to a failure to list a patient for liver trans-
plantation who subsequently died, but reduced speciﬁcity carried
a risk of ‘unnecessary transplantation’ in a patient who was likely
to recover spontaneously. Subsequent modiﬁcations to selection
criteria have tried to address these imbalances but to date the
ideal selection model has not been described (Table 2).
Over the past two decades ALF has undergone signiﬁcant
change that has not been consciously incorporated into the14 vol. 60 j 663–670
Table 1. Determination of prognosis in acute liver failure.
Study Year  Number Patient 
population
Parameters included in study or model Comment
Demographic Laboratory Clinical
Bernuau et al. 1986 115 Hepatitis B Age Factor V levels Clichy criteria
Bismuth et al. 1995 139 Mixed 
aetiologies
Age Factor V levels Grade 3-4 
encephalopathy




Serum bilirubin Jaundice to 
encephalopathy >7 d
KCH criteria
Hadem et al. 2008 102 Mixed 
aetiologies
Aetiology Serum bilirubin, lactate BiLE score
Dhiman et al. 2007 144 Mixed 
aetiologies







Any three of these 6 
parameters
Superior to KCH 
criteria and MELD




Superior to KCH 
criteria and MELD








Superior to KCH 
criteria and MELD
Yantorne et al. 2007 120 Mixed 
aetiologies
MELD score Similar to Clichy 
but superior to KCH 
criteria




O’Grady et al. 1989 431 Paracetamol Arterial pH
INR, serum creatinine Grade 3-4 
encephalopathy
KCH criteria
Bernal et al. 2002 210 Paracetamol Serum lactate Early (3.5 mmol/L) 
and post-resuscitation 
(3.0 mmol/L)
Schmidt & Dalhoff 2002 125 Paracetamol Serum phosphate 
1.2 mmol/L
48-96 h after 
overdose
Schmidt & Larsen 2007 460 Paracetamol MELD score Sensitivity 60%, 
Not superior to KCH 
criteria





Superior to KCH 
criteria and MELD





Applicable from day 3
Sensitivity 100%, 
Escudie et al. 2007 27 Amanita 
phalloides
INR >6.0 at 4 d Diarrhea in <8 h Encephalopathy not 
required
Westbrook et al. 2010 54 Pregnancy-
related





Periera et al. 1992 27 Mixed 
aetiologies
Factor V level <11%
Factor VIII/V ratio <30
Schiodt et al. 2005 182 Mixed 
aetiologies
Protein Gc Predictive in 
non-paracetamol 
aetiologies
Schiodt et al. 2006 206 Mixed 
aetiologies
α-fetoprotein dynamics Increasing levels 
associated with levels 
between days 1 
and 3
KCH, King’s College Hospital; MELD, Mayo End-stage Liver Disease.
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Table 2. Modiﬁed criteria for listing for emergency liver transplantation in UK.
1. Paracetamol-related
2. Paracetamol-related Severe coagulopathy (INR >6.5) and renal failure (anuria or serum creatinine >300 µmol/L) and grade 3-4 
encephalopathy
3. Paracetamol-related
4. Paracetamol-related Any two criteria from category 2 combined with clinical deterioration in the absence of sepsis
5. Other aetiologies Severe coagulopathy (INR >6.5) and any grade of encephalopathy
6. Other aetiologies 3 from 5 of the following – unfavourable aetiology, age >40 yr, jaundice >7 d, serum bilirubin >300 µmol/L, 
INR >3.5 and any grade of encephalopathy
7. Wilson’s disease and 
Budd-Chiari syndrome
Any grade of encephalopathy  
pH <7.25 despite fluid resuscitation
Serum lactate >3.5 on admission or >3.0 after fluid resuscitation
Patients are listed under one category. Most categories are based on the King’s College Hospital criteria or data relating to lactate levels. Category 4 is a pragmatic
modiﬁcation intended to improve sensitivity of patient selection with paracetamol-related ALF. An appeals process evaluates patients not covered by these criteria but
considered to be in need of liver transplantation.
JOURNAL OF HEPATOLOGYselection process for candidates for liver transplantation. In the
King’s College Hospital experience of over 3,300 patients treated
between 1973 and 2008, the hospital survival rate increased from
16.7% to 62.2% [46]. There was an improvement in survival after
transplantation from 66% to 86% but transplant-free survival also
increased to 48%. However, the improved survival without liver
transplantation was not seen across the spectrum of the condi-
tion but was most apparent in paracetamol-related ALF, interme-
diate in other drug-induced cases, and absent in cases of
indeterminate causation [46]. This analysis also demonstrated a
dramatic fall in the incidence of cerebral oedema, traditionally
the most feared complication of ALF, which fell from a peak of
76% to only 20% in the most recent cohort of patients.
There has been considerable interest in ‘bridging’ mechanisms
in ALF that might change the way liver transplantation is utilised.
Liver support devices conceptually offered the potential to bridge
patients with ALF to transplant-free survival but the key random-
ised controlled trials failed to demonstrate this capability for the
condition in its entirety [47,48]. However, subset analyses did
suggest some beneﬁt in patient populations that are broadly sim-
ilar to those in which spontaneous survival rates have been
increasing, e.g., paracetamol-induced ALF, deﬁned viral aetiolo-
gies and hyperacute liver failure. These studies suggest a more
achievable expectation for these devices is a role in bridging
patients to transplantation. Auxiliary liver transplantation is an
elegant concept to ultimately bridge patients to transplant-free
survival and its feasibility has been established with near compa-
rable short-term outcomes as compared with standard transplan-
tation [49–51]. However, the uptake of this transplant option has
remained limited and it accounted for only 2% of activity in
Europe between 1999 and 2009 [22].Listing for liver transplantation
The principles underpinning the selection of patients with ALF are
the accurate identiﬁcation of those in need, as well as those who
will beneﬁt from liver transplantation. One starting point is to
use a set of indicators of a poor prognosis that has gained local con-
ﬁdence with respect to utility and accuracy. In the UK, the listing
criteria introduced in 2007 were largely a pragmatic modiﬁcation
of King’s CollegeHospital criteria to improve sensitivity in paracet-
amol-relatedALF [52]. An alternative opening gambit is to consider
all patients with ALF as potential candidates for liver transplanta-
tion and make the decision as to whether or not to proceed when
a donor organ becomes available.Journal of Hepatology 201The perception of the performance of prognostic models is
strongly inﬂuenced by whether positive or negative predictive
accuracy is deemed to be the most important function. A prefer-
ence for positive predictive accuracy favours the individual patient
but the error rate translates to ‘unnecessary’ transplants. Prefer-
ence for negative predictive accuracy minimises unnecessary
transplants, ensuring that an excessive proportion of a limited
resource is not diverted to the management of patients with ALF,
but the error rate translates to potentially avoidable deaths.
The King’s College Hospital criteria were described in 1989
and were the ﬁrst to differentiate between paracetamol-induced
and other aetiologies of ALF [24]. These have been extensively
used and are acknowledged to have high degree of speciﬁcity
but have been criticised for lack of sensitivity. The criteria have
been subjected to three meta-analyses that reported overall spec-
iﬁcity of 82% for non-paracetamol aetiologies and 92–95% for par-
acetamol-related ALF, respectively [53–55]. In the non-
paracetamol aetiologies, involving 1105 patients in 18 studies,
the speciﬁcity increased to 93% in patients with more advanced
encephalopathy and to 88% when the criteria were applied
dynamically [53]. The reduced sensitivity of the King’s College
Hospital criteria for paracetamol-related ALF was apparent from
the outset as there was a mortality of 17% in patients not meeting
the criteria indicative of a poor outcome [24]. In one meta-
analysis of 1960 patients in 14 studies the sensitivity was consid-
erably lower at 58% but, again, this was considered to have been
reduced by the non-dynamic application of the criteria (often
attributable to the use of prophylactic fresh frozen plasma)
[54]. The second meta-analysis of paracetamol-induced ALF
involved 8 studied and reported a speciﬁcity of 92% but a
sensitivity of 69% [55]. The overall sensitivity in the meta-analysis
of non-paracetamol ALF was 68%, but this fell sharply from 85%
prior to 1995 to 58% after 2005 and was lowest in centres not
offering liver transplantation [53].
MELD scores, introduced and validated for use in prognostica-
tion in chronic liver disease, have been used in ALF and its utility
is not surprising as the 3 components (bilirubin, INR, serum cre-
atinine) ﬁgure strongly in other prognostic models. One of four
studies found that MELD outperformed the King’s College Hospi-
tal criteria in selecting patients for transplantation [27–30]. A
hybrid model based on a study in India combined classical early
indicators of prognosis (age >50 years, jaundice to encephalopa-
thy time greater than 7 days, prothrombin time >35 seconds
and serum creatinine >1.5 mg/dl) with later clinical complica-
tions associated with a poor outcome (advanced encephalopathy
and cerebral oedema) [27]. A recently described prognostic4 vol. 60 j 663–670 665
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model called the Acute Liver Failure Study Group Index combines
three classes of variables – clinical (coma grade), laboratory (INR,
serum bilirubin, phosphorus) and a marker of apoptosis (M30)
[32]. This was considered to outperform both the King’s College
Hospital criteria and MELD with an improved sensitivity of 86%
but this was at the cost of a signiﬁcantly reduced speciﬁcity of
only 65%. A number of disease speciﬁc prognostic models (e.g.,
mushroom poisoning, pregnancy) have also been described but
the parameters utilised are variations of the themes discussed
above rather than radically different approaches [36–39].
Listing for transplantation in the absence of encephalopathy
The presence of encephalopathy is an integral component of def-
inition of ALF. However, it can be argued that in the some circum-
stances the severity of the liver injury is apparent from the extent
of the coagulopathy and postponing a decision on listing for liver
transplantation is wasting valuable time. However, a prospective
study of 68 consecutive patients of mixed aetiologies with severe
acute liver injury deﬁned by a derangement of coagulation fac-
tors (INR >1.7) found that 88% did not progress to encephalopa-
thy and survived without transplantation [56]. The mean INRs
were signiﬁcantly elevated at 4.1 and 6.5 in survivors and non-
survivors, respectively. In this study, serum bilirubin and Factor
VII levels were better predictors of outcome than the INR [56].
The dissociation between an isolated coagulopathy and a poor
outcome is most dramatically seen in paracetamol-related ALF.
In this condition a poor prognosis may be evident before the
onset of encephalopathy, not on the basis of the coagulopathy
but rather the severe acidosis that does not correct rapidly after
ﬂuid resuscitation [24]. This is the only clinical situation where
listing for emergency liver transplantation is permitted for adults
in the UK in the absence of encephalopathy. Children under the
age of two years are also not required to demonstrate encepha-
lopathy prior to listing for liver transplantation.
Adults with sub-acute liver failure represent a subgroup that
arguably is disadvantaged by the need to demonstrable encepha-
lopathy prior to being listed for liver transplantation. This more
indolent variant of ALF typically manifests a less severe derange-
ment of coagulation, oftenwith INR <2, as the serumbilirubin rises
and thediseaseprogresses. Infection is awell recognised trigger for
worsening encephalopathy in ALF [57]. This observation is partic-
ularly pertinent in sub-acute liver failure because when the onset
of encephalopathy is precipitated by infection thismay delay eligi-
bility for liver transplantation or contribute to poorer outcomes
after transplantation. Earlier prediction of the poor outcome in
sub-acute liver failure to facilitatemore timely intervention is cur-
rently an un-met need. At present, the best pre-emptive informa-
tion may be liver volume, as a poor prognosis is suggested by a
progressive reduction as assessed by CT scanning. One study found
a 97% death or transplantation ratewhen the liver volumewas less
than 1,000 ml and although this was not speciﬁc to sub-acute liver
failure this is the clinical situation when this is most frequently
encountered [58].Grafts and graft allocation
Series from specialised centres in the US, continental Europe and
the UK are consistent in showing that around 45–50% of patients
admitted with ALF underwent liver transplantation. The UK ﬁg-666 Journal of Hepatology 201ures exclude cases due to paracetamol as only 7–9% of these
underwent transplantation. Organ allocation systems prioritise
patients with ALF and as a consequence the majority of patients
are transplanted within 4 days of being placed on the waiting list.
Waiting times inﬂuence policy on the use of ABO mismatched
grafts, steatotic livers, liver from non-heart-beating deceased
donors and other sub-optimal potential grafts. European registry
data show that the use of ABO incompatible liver grafts for emer-
gency transplantation was associated with a more than doubling
of the rate of graft loss at 3 months [22]. Living-related donation
is well established in Asia where deceased-donor donation is lim-
ited, but it accounted for only 1.8% of transplant activity for ALF
in Europe between 2004 and 2009 [22].
Full-size organs are used in over 90% of transplants in adults.
Auxiliary orthotopic transplantation peaked at 4% in Europe
between 1994 and 1998 but fell to only 2% in 2004–2009 [22].
Auxiliary transplantation as a bridge to survival without the need
for life-long immunosuppression is an exciting concept [49–51].
The right lobe is typically replaced and the native left lobe is left
in situ and regenerates in about 70% of cases within 1–3 years.
The optimal indications are a combination of the ability of the
native liver to regenerate to normal morphology and the absence
of a clinical syndrome that would beneﬁt from the total removal
of the diseased liver (typically severe neurological complications
or cardiovascular instability and high inotrope requirements).Determinants of outcome
The one-year survival rates based on registry data were 74% in
Europe between 1988 and 2000 and 82% in the US between
1999 and 2008 [22,23]. Survival rates improved considerably
over time to 79% in the European database [22]. Better outcomes
are reported by individual centres, e.g., the King’s College experi-
ence reported 86% post-transplant survival in the latest cohort
(2004–2008) [46]. The overall results are not as good as for trans-
plantation for other indications but compare very favourably to
those seen in patients with chronic liver disease who were in
intensive care or ventilated at the time of organ allocation
(78.6% vs. 64.45 vs. 54.3%, respectively) [23]. It should be noted
that patients receiving liver transplants for ALF are younger than
their counterparts not receiving transplant and markedly youn-
ger than those undergoing elective transplantation. Survival rates
decrease with age as illustrated by European data indicating that
the one and ﬁve-year survival rates are 51% and 42%, respectively,
for patients aged 60 years or older.
Three large studies have attempted to deﬁne the characteris-
tics associated with a poor outcome after liver transplantation for
ALF (Table 3) [22,59,60]. Age was the only factor identiﬁed in all
three studies with a discriminatory threshold of 45 years in one
of these and 50 years in the other two. The higher mortality in
those over 50 years has been attributed to a reduction in physio-
logical reserve [22]. BMI >29 was identiﬁed in one of these stud-
ies, when it had a similar weighting as age over 50 years [59].
None of the studies identiﬁed any speciﬁc characteristics of the
severity of ALF pre-transplant (e.g., severity of coagulopathy) as
predictive of outcome but three broad indicators were identiﬁed
– renal dysfunction (creatinine >2 mg/dl), mechanical ventilation
and inotrope dependence. In terms of deﬁning futility, one study
demonstrated a progressive reduction in survival with accumula-
tion of risk factors from 81% in the low-risk patients (no risk fac-4 vol. 60 j 663–670
Table 3. Determinants of outcome at 90 days after liver transplantation for acute liver failure.
Study Data source Number (yr) Parameters RR






Barshes et al. UNOS registry 1457 (1998-2000) Body mass index >29 1.5
Creatinine >2 mg/dl 1.4
Age >50 yr 1.4
Ventilated 1.4




JOURNAL OF HEPATOLOGYtors) as compared with 42% in the highest-risk group (all four risk
factors) [59]. However, only 2% of patients fell into the highest
risk group and therefore this has very limited capability to deﬁne
futility.
Data from two studies point to the contribution of graft char-
acteristics to outcome, both in terms of ABOmatching and quality
of the graft. ABO identical matches accounted for 72% of trans-
plants in the European experience while 22.4% were compatible
and 5.6% incompatible, and the latter had signiﬁcantly worse out-
comes [22]. The European experience also showed reduced sur-
vival in recipients of split or reduced-sized organs. The impact
of the quality of the matched graft was also demonstrated in a
centre-based study and an equivalent level of increased risk was
identiﬁed for donor age >60 years, non-ABO compatibility, steato-
sis and non-whole organs, which in total accounted for 22% of the
grafts utilised but as high as 29% of the 2000–2004 cohort [52].
The principle of compounding risk was demonstrated in both of
these studies. In the King’s College Hospital series risk was more
than doubled in ABO incompatible grafts that were either split
or steatotic and quadrupled if a non-whole steatotic graft was
used [52]. The study based on the European registry data took a
subpopulation already at increased risk (patients over the age of
50 years) and showed an additional escalating and compounding
risk when the recipient was male, the donor was over the age of
60 years and the ABO-match was incompatible. High donor BMI,
deﬁned as greater than 35 and presumed to be a marker of stea-
tosis, was the single most important determinant of early mortal-
ity in a series of 110 patients with seronegative ALF [53].
Potentially these data could be used to inﬂuence the type of organ
that should not be matched with individual patients.
The cause of death or graft failure could potentially give
insight into the gap in survival rates in ALF as compared with
elective liver transplantation. There is evidence that the legacy
of the neurological and infectious complications of ALF extend
into the post-transplant period. The contribution from neurolog-
ical causes to mortality rates was 13% in both the study based on
UNOS data and the single centre study from the UK, which
extended up to 2004 [59,60]. Since that time there has been a
remarkable reduction in the incidence of cerebral oedema in
the ALF population, which was coincident with an incremental
increase in survival after transplantation to 86% [46]. The ETLRJournal of Hepatology 201and UNOS data attribute death to infection in 18–24% of cases
with an additional 5.6% linked to fungal infection in the UNOS
study [22,59]. These data emphasise the importance of robust
policies for prevention, early diagnosis and treatment of infection
in ALF patients who are potential candidates for liver transplan-
tation. Early referral to specialist centres has also been nominated
as one of the most important contributors to improved outcomes
in ALF and this should be particularly true for patients managed
with liver transplantation [46].Transplant beneﬁt
The original premise supporting the empirical adoption of emer-
gency liver transplantation in ALF holds strongest for subgroups
of patients with an aetiological category of indeterminate aetiol-
ogy/seronegative hepatitis and a phenotypic category of sub-
acute liver failure [61]. The spontaneous survival in these
patients does not exceed 20% and is showing little sign of
improvement. The improvement in survival for seronegative hep-
atitis in the King’s College Hospital from 4.2% pre-1979 to 67.6%
in 2004–2008 was almost entirely due to liver transplantation as
88% of the survivors received grafts [46]. However, at the other
end of the spectrum there is now some doubt about transplant
beneﬁt in patients with paracetamol-related ALF. This is because
of a combination of reduced speciﬁcity in selection, higher mor-
tality on the waiting list, lower survival rates after transplanta-
tion, and improved transplant-free survival rates.
In the King’s College Hospital experience, the overall hospital
survival rate between 1999 and 2008 for patients with paraceta-
mol-related ALF and grade 3 or 4 encephalopathy was 66%. How-
ever, three-quarters of these patients did not receive liver
transplants but still had a survival rate of 52% [46]. A prospective
study of 275 paracetamol-related ALF carried out by the US Acute
Liver Failure Group included 72 patients who were placed on the
waiting list for transplantation [62]. The overall survival rate was
73%, increasing to only 78% after liver transplantation and, most
notably, 59% in patients placed on the waiting-list for transplan-
tation but did not undergo a transplant [54]. There was no statis-
tically signiﬁcant difference in survival after listing for
transplantation based on whether or not a transplant took place4 vol. 60 j 663–670 667
WAIT
• Patients showing sustained evidence of improvement
of prognostic criteria in the absence of clinical
deterioration 
• Paracetamol induced acute liver failure patients who do
not have grade 3 or 4 encephalopathy irrespective of
severity of coagulopathy
• Patients with paracetamol induced acute liver failure
and severe acidosis or elevated serum lactate that
responds rapidly to resuscitative measures
• Most patients when the liver allocated is marginal,
especially steatotic, non-ABO identical or split, ABO-
incompatible or the donor is aged over 60 years
STOP
• Evidence of compromised brainstem function, 
especially  and dilated pupils
• Invasive fungal infection
• Rapidly escalating inotrope requirements
• Severe pancreatitis [usually in paracetamol-related
ALF]
PROCEED 
• Persistence of accepted criteria associated with a poor
prognosis
• Absence of co-morbidity independent of acute liver
failure that would impact on survival
• Absence of complications of acute liver failure
associated with reduced survival
• Absence of psychosocial  suggestive of poor
adaptation of rigour of post-transplant survival
profile
fixed
Fig. 1. Decision making triggers in patients with acute liver failure.
Frontiers in Liver Transplantationbut the sample size should be considered as reasonably small.
Patients listed for liver transplantation with paracetamol-related
ALF had a 2.5-fold higher risk of death on the waiting list as com-
pared with other aetiologies [60]. Finally, there was a 24%
increase in risk of death after liver transplantation and most of
this was due to suicide, trauma or non-adherence to immunosup-
pression regimens and 57% of these deaths occurred within
12 months of transplantation [22].
These data do not readily endorse the practice of routinely
offering liver transplantation in the setting of paracetamol-related
ALF. If the call for randomised controlled trials made in the early
1990s was repeated today, the argument in support would carry
considerable weight. Pragmatically, the design and conduct of
randomised controlled trials in ALF would be extremely challeng-
ing, but in their absence, it is timely to undertake a policy review
for this indication for emergency liver transplantation.
Understanding beneﬁt for an individual patient is clearly
important. The clinical condition for a patient with ALF can change
signiﬁcantly evenwhen the interval between listing for transplan-
tation and the allocation of an organ is less than 72 hours. How-
ever, deﬁning the point when the anticipated outcome no longer
justiﬁes the utilisation of the organ is both difﬁcult from an evi-
dence base and emotive. An outline of some indicators of when
to proceed to transplantation, pause to consider, or abandon a plan
to transplant is presented in Fig. 1. Although the risk stratiﬁcation
studies described above give some insight, these have not gener-
ated the practical clinical end-points to assist decision making.668 Journal of Hepatology 201Objective evidence of brainstem injury with established ﬁxed
and fully dilated pupils should preclude liver transplantation.
Active sepsis is an accepted contraindication to liver transplanta-
tion, but in the context of ALF this can be a difﬁcult diagnosis to
establish or refute. Conﬁrmed systemic fungal infection is another
speciﬁc contraindication to liver transplantation. Inotrope
requirements are an effective surrogatemarker of disease severity
and both absolute levels and the rate of change in dosing require-
ments may indicate a poor outcome with transplantation. In gen-
eral, a pragmatic case by case evaluation of the risk/beneﬁt proﬁle
is employed and this should include consideration of the signiﬁ-
cant contribution the quality of the organ to outcomes.
Key Points
• Liver transplantation is credited with improving survival 
in acute liver failure  
• Listing strategies are imperfect with reduced sensitivity 
risking avoidable deaths and reduced specificity risking 
unnecessary transplantation
• Acute liver failure uses 8% of the organ pool and 
45-50% of non-paracetamol cases seen in specialist 
centres receive transplants 
• Overall survival rates now exceed 60% and early 
referral, reduced frequency of cerebral and emergency 
transplantation have all contributed to this improved 
outcome
• Survival rates after liver transplantation approach 80% 
at 1 year 
• Improvements in non-transplant survival to over 50% 
in some subsets of patients (e.g. paracetamol-related) 
raise doubt about net transplant benefit
• Lack of improvement in non-transplant survival in some 
subsets of patients (e.g. seronegative hepatitis) confirm 
continued transplant benefit
• Clinical recognition of futility is limited but the 
importance of appropriate donor matching is 
recognised as characteristics of the donor organ 
significantly impact on outcome
Conclusions
Liver transplantation has made an enormous contribution to the
improved survival in ALF with over 60% of afﬂicted patients now
expected to survive the illness. However, the application of
liver transplantation has not changed signiﬁcantly over the past
15–20 years despite changes in overall management. The ideal
prognostic model remains illusive with currently used systems
being relatively strong on conﬁrming need in individual patients
but weaker in identifying all those who would beneﬁt from liver
transplantation. Some patient subgroups, exempliﬁed by sero-
negative hepatitis and Wilson’s disease, remain dependent on
liver transplantation for enhanced prospects of survival. In
others, particularly paracetamol-related ALF, the gap between4 vol. 60 j 663–670
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transplant-free and post-transplant survival has narrowed dra-
matically and to the point that a fundamental review of the role
of liver transplantation is indicated. Sub-acute liver failure is an
example of a cohort that is sub-optimally served by liver trans-
plant services, principally because of lack of progress in recognis-
ing the poor prognosis at an early stage. This subgroup is worthy
of focus to deﬁne prognostic and management milestones that
accurately reﬂect the natural history of this condition.Conﬂict of interest
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